BGM Group Ltd. - Class A (BGM) closed at $8.01 on November 11, 2026, unchanged from the previous close, on volume of 1,812 shares (30-day average 14,285).
Data as of November 11, 2026.
No headlines found.
No press releases found.
No news found.
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
BGM Group Ltd. - Class A trades on the NASDAQ stock market under the symbol BGM.
As of November 11, 2026, BGM stock price was flat at $8.01 with 1,812 million shares trading.
BGM has a beta of 2.19, meaning it tends to be more sensitive to market movements. BGM has a correlation of 0.03 to the broad based SPY ETF.
BGM has a market cap of $106.97 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that BGM belongs to (by Net Assets): ONEQ.
BGM has underperformed the market in the last year with a price return of -97.1% while the SPY ETF gained +12.6%. BGM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.1% and -10.8%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
BGM support price is $6.99 and resistance is $9.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BGM shares will trade within this expected range on the day.
